Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:41 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 532296 | NSE: GLENMARK

Glenmark Life Sciences Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹942.30Overvalued by 55.15%vs CMP ₹2,101.00

P/E (21.9) × ROE (15.8%) × BV (₹340.00) × DY (0.12%)

₹547.07Overvalued by 73.96%vs CMP ₹2,101.00
MoS: -284% (Negative)Confidence: 68/100 (Moderate)Models: All 9: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹965.7823%Over (-54%)
Graham NumberEarnings₹537.3216%Over (-74.4%)
Earnings PowerEarnings₹11.8011%Over (-99.4%)
DCFCash Flow₹417.1914%Over (-80.1%)
Net Asset ValueAssets₹339.537%Over (-83.8%)
EV/EBITDAEnterprise₹760.849%Over (-63.8%)
Earnings YieldEarnings₹377.407%Over (-82%)
ROCE CapitalReturns₹473.207%Over (-77.5%)
Revenue MultipleRevenue₹472.055%Over (-77.5%)
Consensus (9 models)₹547.07100%Overvalued
Key Drivers: Wide model spread (₹12–₹966) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 2.5%

*Investments are subject to market risks

Investment Snapshot

61
Glenmark Life Sciences Ltd scores 61/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health72/100 · Strong
ROCE 19.4% GoodROE 15.8% GoodD/E 0.66 ModerateInterest Coverage 0.0x RiskyProfitable 4/5 years Consistent
Smart Money45/100 · Moderate
FII holding down -3.95% (6mo) SellingDII holding up 5.49% MF buyingPromoter holding at 46.7% Stable
Earnings Quality40/100 · Moderate
OPM contracting (19% → 14%) Declining
Quarterly Momentum80/100 · Strong
Revenue (4Q): +25% YoY AcceleratingOPM: 22.0% (up 4.0% YoY) Margin expansion
Industry Rank60/100 · Moderate
P/E 21.9 vs industry 53.8 Cheaper than peersROCE 19.4% vs industry 16.4% Average3Y sales CAGR: 3% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:41 am

Market Cap 59,293 Cr.
Current Price 2,101
Intrinsic Value₹547.07
High / Low 2,298/1,336
Stock P/E21.9
Book Value 340
Dividend Yield0.12 %
ROCE19.4 %
ROE15.8 %
Face Value 1.00
PEG Ratio8.79

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Glenmark Life Sciences Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Glenmark Life Sciences Ltd 59,293 Cr. 2,101 2,298/1,33621.9 3400.12 %19.4 %15.8 % 1.00
Glenmark Pharmaceuticals Ltd 59,293 Cr. 2,101 2,298/1,33621.9 3400.12 %19.4 %15.8 % 1.00
Biocon Ltd 59,196 Cr. 365 425/29572.1 2000.14 %6.25 %4.76 % 5.00
Abbott India Ltd 56,291 Cr. 26,490 37,000/25,35036.9 1,8881.79 %46.2 %35.7 % 10.0
Laurus Labs Ltd 56,080 Cr. 1,039 1,141/51770.0 91.10.12 %9.47 %7.75 % 2.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Glenmark Life Sciences Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 3,1003,0013,0363,2072,5073,0633,2443,4343,3883,2563,2646,0473,901
Expenses 2,6262,6032,5992,7452,7152,5592,6562,8322,7872,6952,6843,6873,031
Operating Profit 474398437462-2095045886026005615812,360870
OPM % 15%13%14%14%-8%16%18%18%18%17%18%39%22%
Other Income 209-696-32-20587351313931-361-297-1,184-140
Interest 9710911212113414940485267586641
Depreciation 152135142141147151118120123125130141154
Profit before tax 435-542151-6-403555462473456896967534
Tax % 33%-26%-14%997%-18%319%26%25%24%45%51%37%24%
Net Profit 291-403173-62-331-1,214340354348447610403
EPS in Rs 9.66-15.185.31-2.90-12.45-43.1712.0612.5512.330.161.6621.6314.29

Last Updated: February 1, 2026, 7:46 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 5:55 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 6,0056,5637,5629,0799,0749,86510,64110,94412,30512,99011,81313,32216,468
Expenses 4,9145,3486,1257,0437,4578,2808,9428,8609,97810,71210,61810,97012,097
Operating Profit 1,0911,2141,4372,0371,6171,5861,6992,0842,3272,2781,1952,3514,371
OPM % 18%18%19%22%18%16%16%19%19%18%10%18%27%
Other Income 11-18020-448937519195-101-449336-259-1,982
Interest 189190179237286335377353298350516207233
Depreciation 217300234264302326417444487611582486551
Profit before tax 6975441,0441,4911,1191,3011,0961,3821,4418684341,3991,605
Tax % 22%61%29%26%28%29%29%30%31%57%430%25%
Net Profit 5462097431,109804925776970994377-1,4341,0471,065
EPS in Rs 19.997.7226.3339.2928.4932.7827.5034.3833.3710.53-53.2237.1137.74
Dividend Payout % 0%26%8%5%7%6%9%7%7%24%-5%7%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-61.72%255.50%49.26%-27.50%15.05%-16.11%25.00%2.47%-62.07%-480.37%173.01%
Change in YoY Net Profit Growth (%)0.00%317.22%-206.24%-76.76%42.55%-31.16%41.11%-22.53%-64.55%-418.30%653.38%

Glenmark Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:7%
5 Years:5%
3 Years:3%
TTM:11%
Compounded Profit Growth
10 Years:17%
5 Years:12%
3 Years:6%
TTM:159%
Stock Price CAGR
10 Years:7%
5 Years:33%
3 Years:74%
1 Year:16%
Return on Equity
10 Years:6%
5 Years:-1%
3 Years:-10%
Last Year:16%

Last Updated: September 5, 2025, 3:36 pm

Balance Sheet

Last Updated: December 4, 2025, 2:57 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 27272828282828282828282828
Reserves 2,9561,7563,6014,4645,1355,5776,0427,0369,0589,4467,8208,8219,554
Borrowings 3,2673,8003,9884,7244,6394,4494,8694,9863,9624,6271,2312,4731,224
Other Liabilities 2,1762,7262,5752,5482,7933,2353,7293,5244,0035,2285,2794,6698,196
Total Liabilities 8,4278,30910,19311,76412,59513,28914,66815,57517,05219,32914,35815,99119,002
Fixed Assets 3,0912,0152,5942,7553,0303,6705,0295,1295,8876,2024,2104,4875,210
CWIP 54775437081,1221,3991,2221,3821,0101,251662835695
Investments 01717161530252550457905642
Other Assets 5,3315,7997,0398,2858,4298,1908,3939,04010,10511,8308,69710,61313,054
Total Assets 8,4278,30910,19311,76412,59513,28914,66815,57517,05219,32914,35815,99119,002

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 8544823456571,6481,3241,3921,1311,109625-265-828
Cash from Investing Activity + -566-712-950-1,001-1,003-883-774-662-316-5154,38758
Cash from Financing Activity + -98199699543-468-739-445-442-520-77-3,906787
Net Cash Flow 190-3193199177-297174282723221517
Free Cash Flow 481-56-544-7662571261645632375-1,162-1,575
CFO/OP 102%66%57%67%124%111%109%79%72%56%65%-6%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-2.00-2.00-2.00-2.00-3.00-3.00-3.00-2.00-1.00-2.000.000.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 1311401209794818386921155792
Inventory Days 191247249299244244211230208203208254
Days Payable 279379308243225241210226190172210216
Cash Conversion Cycle 4386115211385849011014756129
Working Capital Days 6247511259964546765141-244
ROCE %15%16%19%21%15%15%14%15%16%10%12%19%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 46.65%46.65%46.65%46.65%46.65%46.65%46.65%46.65%46.65%46.64%46.64%46.65%
FIIs 22.47%25.51%24.79%23.71%21.38%20.98%23.05%23.51%23.15%20.62%20.73%19.20%
DIIs 10.40%9.10%10.31%10.92%13.36%13.93%13.21%13.85%14.60%17.64%18.61%20.09%
Government 0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%
Public 20.46%18.70%18.21%18.70%18.58%18.42%17.06%15.96%15.56%15.05%13.97%14.02%
No. of Shareholders 2,85,4612,36,9082,32,6852,09,9311,99,4511,92,6301,93,9491,95,0591,92,7241,90,2101,98,7892,01,584

Shareholding Pattern Chart

No. of Shareholders

Glenmark Life Sciences Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HDFC Mid Cap Fund 12,815,305 2.91 2738.2512,675,4402026-03-23 11:32:571.1%
Invesco India Midcap Fund 1,864,031 3.7 398.29N/AN/AN/A
Invesco India Contra Fund 1,850,088 1.98 395.311,662,2352025-12-15 01:33:0511.3%
Invesco India Large & Mid Cap Fund 1,342,939 3.06 286.951,205,1072025-11-03 01:08:2111.44%
HDFC Large and Mid Cap Fund 1,048,046 0.78 223.94N/AN/AN/A
Mahindra Manulife Multi Cap Fund 989,000 3.42 211.32N/AN/AN/A
Bandhan Small Cap Fund 952,877 0.99 203.6N/AN/AN/A
Mirae Asset Healthcare Fund 922,543 6.93 197.12916,0432026-03-23 03:14:070.71%
HDFC Balanced Advantage Fund 885,046 0.18 189.11N/AN/AN/A
UTI Value Fund 800,000 1.75 170.94N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 37.11-53.2210.5333.3734.38
Diluted EPS (Rs.) 37.11-53.2210.5333.3734.38
Cash EPS (Rs.) 54.33-30.1835.0452.4650.10
Book Value[Excl.RevalReserv]/Share (Rs.) 313.60278.09348.70334.48250.36
Book Value[Incl.RevalReserv]/Share (Rs.) 313.60278.09348.70334.48250.36
Revenue From Operations / Share (Rs.) 472.08418.62460.36436.08387.85
PBDIT / Share (Rs.) 87.3672.1391.9788.1475.65
PBIT / Share (Rs.) 70.1351.5070.3170.8959.93
PBT / Share (Rs.) 49.581.2930.7851.0848.99
Net Profit / Share (Rs.) 37.11-50.8013.3735.2134.38
NP After MI And SOA / Share (Rs.) 37.11-53.2110.5333.3734.38
PBDIT Margin (%) 18.5017.2219.9720.2119.50
PBIT Margin (%) 14.8512.3015.2716.2515.45
PBT Margin (%) 10.500.306.6811.7112.63
Net Profit Margin (%) 7.86-12.132.908.078.86
NP After MI And SOA Margin (%) 7.86-12.712.287.658.86
Return on Networth / Equity (%) 11.83-19.133.1310.3613.73
Return on Capital Employeed (%) 19.6217.0113.8416.1314.83
Return On Assets (%) 6.52-10.451.535.516.21
Long Term Debt / Equity (X) 0.050.000.400.280.55
Total Debt / Equity (X) 0.240.120.450.400.66
Asset Turnover Ratio (%) 0.870.700.710.420.42
Current Ratio (X) 1.561.281.961.771.75
Quick Ratio (X) 1.050.841.371.231.21
Inventory Turnover Ratio (X) 4.811.151.311.851.85
Dividend Payout Ratio (NP) (%) 6.73-4.6923.737.497.27
Dividend Payout Ratio (CP) (%) 4.60-7.667.764.934.99
Earning Retention Ratio (%) 93.27104.6976.2792.5192.73
Cash Earning Retention Ratio (%) 95.40107.6692.2495.0795.01
Interest Coverage Ratio (X) 11.903.947.428.346.04
Interest Coverage Ratio (Post Tax) (X) 7.86-0.804.275.213.62
Enterprise Value (Cr.) 43947.2726350.4516364.2715087.8616656.12
EV / Net Operating Revenue (X) 3.302.231.261.231.52
EV / EBITDA (X) 17.8312.956.316.077.80
MarketCap / Net Operating Revenue (X) 3.262.291.011.011.20
Retention Ratios (%) 93.26104.6976.2692.5092.72
Price / BV (X) 4.913.441.381.371.86
Price / Net Operating Revenue (X) 3.262.291.011.011.20
EarningsYield 0.02-0.050.020.070.07

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Glenmark Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 9226.41 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsB/2, Mahalaxmi Chambers, Mumbai Maharashtra 400026Contact not found
Management
NamePosition Held
Mr. Glenn SaldanhaChairman & Managing Director
Mrs. Cherylann PintoExecutive Director
Mr. Anurag MantriExecutive Director & Global CFO
Mrs. B E SaldanhaNon Executive Director
Ms. Saira RamasastryInd. Non-Executive Director
Mrs. Vijayalakshmi IyerInd. Non-Executive Director
Mr. Pradeep Kumar SinhaInd. Non-Executive Director
Mr. Dipankar BhattacharjeeInd. Non-Executive Director

FAQ

What is the intrinsic value of Glenmark Life Sciences Ltd and is it undervalued?

As of 13 April 2026, Glenmark Life Sciences Ltd's intrinsic value is ₹547.07, which is 73.96% lower than the current market price of ₹2,101.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (15.8 %), book value (₹340), dividend yield (0.12 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Glenmark Life Sciences Ltd?

Glenmark Life Sciences Ltd is trading at ₹2,101.00 as of 13 April 2026, with a FY2026-2027 high of ₹2,298 and low of ₹1,336. The stock is currently near its 52-week high. Market cap stands at ₹59,293 Cr..

How does Glenmark Life Sciences Ltd's P/E ratio compare to its industry?

Glenmark Life Sciences Ltd has a P/E ratio of 21.9, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Glenmark Life Sciences Ltd financially healthy?

Key indicators for Glenmark Life Sciences Ltd: ROCE of 19.4 % indicates efficient capital utilization; ROE of 15.8 % shows strong shareholder returns. Dividend yield is 0.12 %.

Is Glenmark Life Sciences Ltd profitable and how is the profit trend?

Glenmark Life Sciences Ltd reported a net profit of ₹1,047 Cr in Mar 2025 on revenue of ₹13,322 Cr. Compared to ₹994 Cr in Mar 2022, the net profit shows an improving trend.

Does Glenmark Life Sciences Ltd pay dividends?

Glenmark Life Sciences Ltd has a dividend yield of 0.12 % at the current price of ₹2,101.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Glenmark Life Sciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports